Why is the NIB (ASX:NHF) share price sliding 7% today?

JP Morgan is now bearish on NIB and reckons further downside is imminent.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Downward red arrow with business man sliding down it signifying falling asx share price.

Image source: Getty Images

Key points

  • JP Morgan downgraded NIB to underweight today
  • The broker slashed its price target by 12% to $6.10
  • The firm is cautious on the Australian health insurance sector over the medium to long-term
  • Analysts at the firm like Medibank as a better alternative
  • In the last 12 months the NIB share price has climbed more than 11%

Shares in private health insurer NIB Holdings Limited (ASX: NHF) are plunging more than 7% from the open today and now trade at $6.16 apiece.

Investors are selling the NIB share price today following a broker downgrade from investment bank JP Morgan.

In a note to clients, the broker deconstructs why NIB has fallen out of the limelight, and why it urges its clients to sell the insurer. Let's take a look.

Why's the NIB share price plunging today?

In the absence of any market-sensitive information from the company's camp today, it could be that JP Morgan slashed its price target for NIB by 12% to $6.10.

In doing so, it also assigned an underweight recommendation on the stock, downgrading the insurer from a previous neutral rating.

The broker reckons that insures such as NIB and Medibank Private Ltd (ASX: MPL) have benefitted tremendously from a slowdown in COVID-19 health claims in the short term.

However, it also notes that NIB has made promises that policyholders will see benefits returned to them, which poses a risk to long-term profits.

The broker isn't so rosy on the outlook of the Australian health insurance sector over the medium to long-term, noting widening capital requirements, lower rate increases and headwinds to profits in some business lines.

Specifically, the investment bank alludes to NIB's Australian Residents Health Insurance unit that appears to be struggling based on the numbers.

JP Morgan reckons that NIB will overreach its margin targets in this segment once again, especially due to its stance on retaining COVID-19 benefits for shareholders.

Analysts at the firm like Medibank as a better alternative, although the team also downgraded its view on NIB's rival to underweight as well today.

Shares have faltered after the broker released its scathing cross-examination on NIB, and are now trading at their lowest level in almost 6 months.

As seen on the chart below, both shares have tracked each other fairly closely over the last 12 months, with the exception of NIB's breakout-correction phase in August last year.

TradingView Chart

Hence, it appears we might be at a crossroads between the pair and the next course of direction in their share prices.

NIB share price snapshot

In the last 12 months, the NIB share price has climbed more than 11%. Since January 1 this year however, it has slipped well into the red and is 12% down.

Not only that, but in the last week of trading, shares have fallen another 6% amid a market-wide selloff that's been in situ since December last year.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended NIB Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

gold, gold miner, gold discovery, gold nugget, gold price,
Broker Notes

With the gold price up on Monday, are Northern Star shares a good buy now?

A leading analyst provides his outlook for Northern Star’s shares.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Brokers believe that now could be the time to buy these shares.

Read more »

An oil refinery worker stands in front of an oil rig with his arms crossed and a smile on his face.
Broker Notes

Up 23% this year, should I buy Woodside shares today?

A leading analyst provides his outlook for Woodside’s outperforming shares.

Read more »

Woman and man calculating a dividend yield.
Broker Notes

Buy, hold, sell: JB Hi-Fi, Westpac, Santos shares

Experts explain their buy, hold, and sell recommendations on these 3 ASX 200 shares.

Read more »

A person leans over to whisper a secret to a colleague during a meeting.
Broker Notes

Buy, hold, sell: Life360, Woodside, CSL shares

The market is lower today as two experts explain their ratings on these three ASX 200 shares. 

Read more »

A group of business people sit dejectedly around a table, each expressing desolation, sadness, and disappointment by holding their head in their hands, casting their gazes down and looking very glum.
Broker Notes

Why CSL, Westpac, and this big-name ASX 200 share could be sells

Experts are feeling bearish about these big names. Let's find out why.

Read more »

A man holding a cup of coffee puts his thumb up and smiles with a laptop open.
Broker Notes

Experts name 3 ASX 200 shares to buy

These shares are highly rated by experts for different reasons.

Read more »

Two male ASX 200 analysts stand in an office looking at various computer screens showing share prices.
Broker Notes

8 ASX shares with 30% to 220% upside ahead: Experts

We reveal the 12-month share price targets just set by brokers on these eight ASX stocks.

Read more »